Abstract: A process for preparing a composition including a bioactive molecule including the steps of a. Dissolving a bioactive molecule having at least one acid group with a base at pH=>11 to obtain a solution A b. Neutralizing the solution A with an acid to obtain the composition including the bioactive molecule having a pH between 6 and 9, wherein PEG is added before the neutralizing step in case either the base and/or the acid is an inorganic compound, and to a composition including a high concentration of natamycin.

Abstract: Provided herein, inter alia, is a modular-functional technology for the expression of a functional heterologous polyketide synthases (PKS) system in a photosynthetic cyanobacteria.

Abstract: The present invention relates to polynucleotide sequences which enable a polynucleotide control sequence, such as a promoter, to direct expression in a wide range of industrially relevant species, both prokaryotes and eukaryotes. When the polynucleotide sequences of the invention are applied in combination with selection marker genes it is possible to perform selectable cloning in a laboratory host and use the same construct in the final host.

Abstract: Embodiments of the invention are directed of compositions for activation or inhibition of the Oct?2 receptor and uses thereof. The inventors have discovered that the beta adrenergic-like octopamine receptor Oct?2 serves as a key signaling molecule for ovulation and recruits protein kinase A and Ca2+/calmodulin-sensitive kinase II as downstream effectors for this activity. Oct?2R homozygous mutant females are sterile, and display normal courtship, copulation, sperm storage and post-mating rejection behavior but were unable to lay eggs.

Abstract: Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar activity. This invention is directed to compositions enriched for particular occidiofungin diastereomers/conformers, methods of making compositions enriched for particular diastereomers/conformers and microorganisms suitable for producing enriched compositions of particular diastereomers/conformers. Methods of treating fungal infections or plants infected by fungi are also provided.

Abstract: The present invention relates to 25 hitherto undescribed genes of B. licheniformis and gene products derived therefrom and all sufficiently homologous nucleic acids and proteins thereof. They occur in five different metabolic pathways for the formation of odorous substances. The metabolic pathways in question are for the synthesis of: 1) isovalerian acid (as part of the catabolism of leucine), 2) 2-methylbutyric acid and/or isobutyric acid (as part of the catabolism of valine and/or isoleucine), 3) butanol and/or butyric acid (as part of the metabolism of butyric acid), 4) propyl acid (as part of the metabolism of propionate) and/or 5) cadaverine and/or putrescine (as parts of the catabolism of lysine and/or arginine).

Abstract: The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. One important area is the isolation and potential use of novel FKBP-ligand analogs and host cells that produce these compounds. The invention is particularly concerned with methods for the efficient transformation of strains that produce FKBP analogs and recombinant cells in which cloned genes or gene cassettes are expressed to generate novel compounds such as polyketide (especially rapamycin) FKBP-ligand analogs, and to processes for their preparation, and to means employed therein (e.g. nucleic acids, vectors, gene cassettes and genetically modified strains).

Abstract: The present invention relates to methods of use of glycosyltransferases and related novel compounds. The invention exploits the reversibility of glycosyltransferases to generate new sugars, unnatural biomolecules and numerous one-pot reactions for generation of new biomolecules having varied backbones such as enediynes, vancomycins, bleomycins, anthracyclines, macrolides, pluramycins, aureolic acids, indolocarbazoles, aminglycosides, glycopeptides, polyenes, coumarins, benzoisochromanequinones, calicheamicins, erythromycin, avermectins, ivermectins, angucyclines, cardiac glycosides, steroids or flavinoids. In preferred embodiments, the invention specifically relates to biosynthesis of anticancer (the enediyne calicheamicin, CLM), anthelmintic agents (the macrolides avermectin, ivermectin and erythromycin) and antibiotic (the glycopeptide vancomycin, VCM) natural product-based drugs developed by reversible, bidirectional glycosyltransferase-catalyzed reactions.

Abstract: This invention relates to metabolically engineered microorganism strains, such as bacterial strains, in which there is an increased utilization of malonyl-CoA for production of a chemical product, which includes polyketides and 3-hydroxypropionic acid.

Abstract: The present invention relates to a novel polyene compound similar to nystatin, a method for preparing the same, and an antifungal drug comprising the novel polyene compound as an active ingredient. Compared to nystatin comprising one sugar, NNP, which is the polyene compound similar to nystatin, displays 300 times higher solubility and ten times lower cytotoxicity while maintaining antifungal activity, and thus can be useful in developing a novel polyene antifungal agent having improved solubility and less toxicity in terms of pharmacokinetics.

Abstract: Fermentation media containing an isoflavone-depleted soybean meal or isoflavone-depleted soybean meal product and at least one exogenous added ingredient that comprises a substrate for microbial growth are provided. Methods of making a fermentation medium comprising an isoflavone-depleted soybean meal or isoflavone-depleted soybean meal product and methods for obtaining a fermentation product are also provided. The present invention is further directed to fermentation broths obtained by the media and methods. The present invention is also directed to feed additives produced from fermentation broths obtained by the methods.

Abstract: The invention describes the integration of polynucleotides into chromosomal DNA of S. spinosa species, which are useful for the production of insecticides, integrants thereof, and also to the use of the integrants. The invention includes the stable integration and expression of an oxygen-binding protein, VHb, which results in increased spinosyn production.

Abstract: Disclosed are levoisovalerylspiramycin I, II or III, preparations, preparing methods and uses thereof. The preparations comprise levoisovalerylspiramycin I, II or III and pharmaceutically acceptable carrier and/or adjuvant, wherein the purity of levoisovalerylspiramycin I, II or III is above 90 wt %. The levoisovalerylspiramycin I, II or III has a good antibacterial activity, and the preparations include solution for injection, powder for injection or lyophilized powder for injection.

Abstract: Novel extender units for Type I polyketide synthases are provided. Also provided are genes, compounds, and methods for generating these units, and for incorporation of the novel extender units into polyketides for the purpose of generating new structural derivatives of polyketide-containing products.

Abstract: A genetically engineered strain WSJ-IA for producing isovaleryl spiramycin I. Also provided is a method for preparing the strain, including the steps of: (a) constructing a recombinant plasmid including a double gene ist-acyB2; (b) transforming the plasmid into an isovaleryl spiramycin I-producing strain to obtain the strain WSJ-IA. The level of isovaleryl spiramycin I produced by fermentation of the strain WSJ-IA is increased 1.7 times and the fermentation potency thereof increased 4.14 times in comparison with the strain exclusively including a single gene ist.

Abstract: The invention describes the integration of polynucleotides into chromosomal DNA of S. spinosa species, which are useful for the production of insecticides, integrants thereof, and also to the use of the integrants. The invention includes the stable integration and expression of an oxygen-binding protein, VHb, which results in increased spinosyn production.

Abstract: Bioreactors, and particularly, photobioreactors having a reactor chamber and surge driver, and methods for using these devices, for example, for the production of carbon-based products are provided. The reactor chamber provides a housing for microorganisms and culture medium. The surge driver produces a surge of the microorganisms and/or culture medium in the reactor chamber.

Abstract: The present invention relates to Stambomycin compounds, their derivatives and their pharmaceutically acceptable salt thereof.

Abstract: The invention provides, biologically active spinosyns, hybrid spinosyn polyketide synthases capable of functioning in Saccharopolyspora spinosa to produce the spinosyns, and methods of controlling insects using the spinosyns.

Abstract: Fermentation media containing an isoflavone-depleted soybean meal or isoflavone-depleted soybean meal product and at least one exogenous added ingredient that comprises a substrate for microbial growth are provided. Methods of making a fermentation medium comprising an isoflavone-depleted soybean meal or isoflavone-depleted soybean meal product and methods for obtaining a fermentation product are also provided. The present invention is further directed to fermentation broths obtained by the media and methods. The present invention is also directed to feed additives produced from fermentation broths obtained by the methods.

Abstract: The present invention relates to a process for the production of tiacumicin B which comprises fermentation of a micro-organism of the species Dactylosporangium aurantiacum in a culture broth containing polysaccharides such as cellulose and derivatives thereof.

Abstract: This disclosure concerns methods for producing a spinosyn producing strain that comprises modifying a nucleic acid molecule encoding for spinactin by introducing, mutating, deleting, replacing or inactivating a nucleic acid sequence encoding one or more activities encoded by said nucleic acid molecule. Methods for producing a modified Saccharopolyspora spinosa organism are also disclosed.

Abstract: The present invention relates to levocarrimycin, its pharmaceutical compositions, preparation methods and application. Levocarrimycin is a mixture of isovalerylspiramycin III, II and I as main components and contains some isobutyrylspiramycin III and II, butyrylspiramycin III and II, propionylspiramycin III and II, as well as acetylspiramycin III and II, among which, the content of isovalerylspiramycin III is no less than 30 wt %, the total content of isovalerylspiramycin III, II and I is no less than 60 wt %, and the content of acylspiramycin is 80-98 wt %. Specific optical rotation of said levocarrimycin is [?]D=?52°˜?57° in the solution of 0.02 g/ml chloroform at temperature of 25° C. The present invention also relates to the crystalline compound of isovalerylspiramycin III, II or I in levocarrimycin, and pharmaceutical compositions containing the said levocarrimycin.

Abstract: This invention relates to metabolically engineered microorganism strains, such as bacterial strains, in which there is an increased utilization of malonyl-CoA for production of a chemical product, which includes polyketides and 3-hydroxypropionic acid.

Abstract: Methods, processes and materials for the production and recovery of Tiacumicins produced by culturing a microorganism belonging to the species Dactylosporangium aurantiacum subspecies hamdenensis having the ability to produce and accumulate one or more Tiacumicin in a nutrient medium comprising a carbon source, a nitrogen source, trace elements such as inorganic salts, and an adsorbent, wherein said nitrogen source comprises fish powder, and wherein said Tiacumicin is produced in a yield greater than about 50 mg/L broth.

Abstract: Disclosed are levoisovalerylspiramycin I, II or III, preparations, preparing methods and uses thereof. The preparations comprise levoisovalerylspiramycin I, II or III and pharmaceutically acceptable carrier and/or adjuvant, wherein the purity of levoisovalerylspiramycin I, II or III is above 90 wt %. The levoisovalerylspiramycin I, II or III has a good antibacterial activity, and the preparations include solution for injection, powder for injection or lyophilized powder for injection.

Abstract: Seven novel antibiotic substances can be produced by cultivation of a microbial strain which has been isolated from a soil sample and which is designated as Microbispora sp. A 34030 (deposited under an access number FERM BP-10505 in terms of Budapest Treaty). These seven antibiotic substances are named as bispolide A1, bispolide A2, bispolide A3, bispolide B1, bispolide B2a, bispolide B2b and bispolide B3, respectively. These bispolides are each novel compounds which have a chemical structure as collectively represented by the general formula (III) shown below: These bispolides have each a high antibacterial activity against a variety of bacteria, particularly Gram-positive bacteria and their antibiotic-resistant strains, and hence these bispolides each are effective and useful for therapeutically treating bacterial infections of Gram-positive bacteria in humans and animals.

Abstract: The invention describes the integration of polynucleotides into chromosomal DNA of S. spinosa species, which are useful for the production of insecticides, integrants thereof, and also to the use of the integrants. The invention includes the stable integration and expression of an oxygen-binding protein, VHb, which results in increased spinosyn production.

Abstract: The present invention provides regio- and stereoselective oxidation of unactivated C—H bonds using an engineered mutant cytochrome P450 monooxygenase and an engineered substrate.

Abstract: The present invention relates to Stambomycin compounds, their derivatives and their pharmaceutically acceptable salt thereof.

Abstract: A microbial ethyl esther sophorolipid derivative with no acetylated groups produced by Candida species, for treating and preventing sepsis/septic shock. The method of producing sophorolipids is through microbial resting cells of Candida bombicola. The sophorolipids obtained from resting state cultures are isolated as a complex mixture of compounds and then decanted as a dense oil from the culture broth, subsequently washed to remove free fatty acids. Secondary chemical transformation via base catalyzed hydrolysis is used to reduce the 8 possible structural sophorolipid species to a single moiety, the 17-L-[(2?-O-b-D-glucopyranosyl-b-D-glucopyranosyl)-oxy]-cis-9-octadecenoate de-acetylated free acid. The compound acts primarily through decreasing inflammatory cytokines and eliciting other synergistic anti-inflammatory mechanisms by blocking TLR4-CD14 upstream of the inflammatory signaling cascade.

Abstract: This disclosure describes the molecular cloning of an enduracidin biosynthetic gene cluster from Streptomyces fungicidicus, and characterization of individual genes in the gene cluster and the proteins encoded thereby. An enduracidin gene cluster is located within a 116 kilobases genetic locus and includes 25 open reading frames (ORFs). An additional 23 ORFs flank the disclosed enduracidin biosynthetic gene cluster. Enduracidin analogs and a method for producing them by manipulation of the enduracidin gene cluster and specific genes therein are also disclosed.

Abstract: The invention relates to the synthesis of polyketides in Actinomycetes by overexpression of pantothenate kinase and supplementation with pantothenic acid. This results in increasing in vivo CoA production and thereby drives increased production of secondary metabolites, such as polyketides.

Abstract: Genetically modified E. coli strains capable of producing erythromycins, particularly erythromycin A.

Abstract: Provided are nucleic acid molecules comprising at least a functional fragment of the capreomycin biosynthetic gene cluster, polypeptides encoded by the cluster and recombinant host cells transformed with any of the nucleic acid molecules disclosed herein. Various methods using any of the vectors or expression cassettes that encode one or more of the gene products of the cluster are provided for heterologous production of capreomycin and capreomycin derivatives.

Abstract: The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding an aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of S. avermitilis. The present invention further relates to vectors, host cells, and mutant strains of S. avermitilis in which the aveC gene has been inactivated, or mutated so as to change the ratio or amount of class 2:1 avermectins produced.

Abstract: The invention provides, biologically active spinosyns, hybrid spinosyn polyketide synthases capable of functioning in Saccharopolyspora spinosa to produce the spinosyns, and methods of controlling insects using the spinosyns.

Abstract: The present invention relates to fungal strains capable of producing insecticide and a process for production of insecticide. It also relates to a method of cultivation of fungal strains and a fermentation medium for culturing the fungal strains.

Abstract: Host cells comprising recombinant vectors encoding the FK-520 polyketide synthase and FK-520 modification enzymes can be used to produce the FK-520 polyketide. Recombinant DNA constructs comprising one or more FK-520 polyketide synthase domains, modules, open reading frames, and variants thereof can be used to produce recombinant polyketide synthases and a variety of different polyketides with application as pharmaceutical and veterinary products.

Abstract: The invention provides a nucleic acid molecule comprising: (a) a nucleotide sequence as shown in SEQ ID No. 35; or (b) a nucleotide sequence which is the complement of SEQ ID No. 35; or (c) a nucleotide sequence which is degenerate with SEQ ID No. 35; or (d) a nucleotide sequence hybridising under conditions of high stringency to SEQ ID No. 35, to the complement of SEQ ID No. 35, or to a hybridisation probe derived from SEQ ID No. 35 or the complement thereof; or (e) a nucleotide sequence having at least 80% sequence identity with SEQ ID No. 35; or (f) a nucleotide sequence having at least 65% sequence identity with SEQ ID No. 35 wherein said sequence preferably encodes or is complementary to a sequence encoding a nystatin PKS enzyme or a part thereof.

Abstract: Methods for the computational analysis of polyketides and the computer-assisted design of PKS genes are facilitated by representing the structure of a polyketide and/or a PKS gene that encodes the PKS that produces the polyketide by alphanumeric symbols that facilitates computer assisted analysis. A database of polyketides and corresponding PKS genes that can be rapidly searched and information extracted for a variety of applications, including the design and specification of PKS genes via the recombining of modules or portions of modules or sets of modules from already known and available PKS genes.

Abstract: The present invention provides a method for stabilizing a macrolide compound, and an efficient method for producing the compound. Specifically, it provides a method for stabilizing a macrolide compound, in which a 12-membered ring macrolide compound, such as a compound expressed by the formula (1) and a cyclodextrin are both present, and a method for producing a macrolide compound, in which a cyclodextrin is made to be present in a culture broth of actinomycetes having an ability of producing the macrolide compound.

Abstract: A process of increasing the cellular production of biologically active compounds is provided. The process is particularly useful for increasing antibiotic production by bacterial cells. The process includes the step of inhibiting the activity of methylmalonyl-CoA mutase.

Abstract: The invention provides, biologically active spinosyns, hybrid spinosyn polyketide synthases capable of functioning in Saccharopolyspora spinosa to produce the spinosyns, and methods of controlling insects using the spinosyns.

Abstract: The present invention relates to the base sequence of whole genes involved in the biosynthesis of FR-008 polyketides derived from Streptomyces sp. FR-008. This base sequence comprises genes coding for ketosynthase (KS), acyl transferase (AT), acyl carrier protein (ACP), ketoreductase (KR), dehydratase (DH) and enoyl reductase (ER) domains, and genes coding for modifier enzymes, such as ABC transporter, cytochrome P450 monooxygenase, ferredoxin, thioesterase, sugar synthetic protein, FAD-dependent monooxygenase, 4-amino-4-deoxychorismate (ADC) synthase and ADC lyase. The gene base sequence according to the present invention can be used to increase the productivity of the existing FR-008 polyketides or produce new FR-008 polyketides, through modification of its parts.

Abstract: The invention relates to novel polyenes having formula (I), wherein: R1 represents alkyl C1-C3; and R2 represents a functional group selected from CH3— or CONH2— (methyl- or primary amide-). The aforementioned polyenes have a biocide action on organisms comprising cell membranes that contain ergosterol, e.g., fungi or parasites. Said compounds can be obtained using a method that consists in cultivating a producing micro-organism under conditions that enable the production thereof. In addition, the invention also relates to a mechanism for the in vitro production of amidated polyenes, consisting in incubating carboxylated polyenes with cell-free extracts (or proteinaceous fractions) of the producers of same in the presence of ATP/Mg++ and an amide- group donor compound (preferably glutamine).

Abstract: The present invention relates to the biosynthesis of polyketides and derives from the cloning of nucleic acids encoding a polyketide synthase and other associated proteins involved in the synthesis of the polyketide borrelidin. Materials and methods including enzyme systems, nucleic acids, vectors and cells are provided for the preparation of polyketides including borrelidin and analogues and derivatives thereof. Novel polyketide molecules are also provided.

Abstract: A novel family of cyclic polyene natural products isolated from marine actinomycete strain CNQ140 is provided. This novel strain of actinomycetes was obtained from a previously unstudied population of marine actinomycetes that reside in sediments off La Jolla, Calif. Compounds derived from strain CNQ140 have been characterized as having a cyclic polyene-polyol structure; a molecular weight from about 996 to about 1010 in the core ring structure; and at least 58 carbons and at least 14 oxygens. The invention compounds have antitumor and/or anti-microbial activity.

Abstract: During the production of a product compound by fermentation, the concentration of a precursor compound is maintained within a pre-selected concentration range by having an adsorbent resin in contact with the culture medium. The adsorbent resin reversibly adsorbs precursor compound and, as un-adsorbed precursor compound is converted to product compound, adsorbed precursor compound is released from the resin, thus maintaining the concentration of precursor compound within the pre-selected range.

Abstract: Host cells, such as E. coli, are provided with an expression system for making starter units required for biosynthesis of polyketides using the ato pathway.